Results 131 to 140 of about 118,840 (299)

ProTides for Antiviral Activity Beyond Liver Cells

Chemistry – A European Journal, EarlyView.
A strategy for obtaining prodrugs of antiviral nucleotides with broad tissue activity is presented that relies on cycloalkyl or cycloalkylalkyl esters, improving uptake and esterase cleavage, and producing nanomolar inhibitors in kidney, colon, and lung cells.
Felix Goebel, Adrian Humboldt, Heeyoung Kim, Carl J. M. Schölzel, Ralf Bartenschlager, Clemens Richert   +5 more
wiley   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Hederacolchiside A1 Suppresses Autophagy by Inhibiting Cathepsin C and Reduces the Growth of Colon Cancer. [PDF]

Cancers (Basel), 2023
Kim S, Lee KH, Choi HJ, Kim E, Kang S, Han M, Jeon HJ, Yun MY, Song GY, Lee HJ.   +9 more
europepmc   +1 more source

Inconsistent Transcriptomic Responses to Hexabromocyclododecane in Japanese Quail: A Comparative Analysis of Results From Four Different Study Designs

Environmental Toxicology and Chemistry, EarlyView.
Abstract Efforts to use transcriptomics for toxicity testing have classically relied on the assumption that chemicals consistently produce characteristic transcriptomic signatures that are reflective of their mechanism of action. However, the degree to which transcriptomic responses are conserved across different test methodologies has seldom been ...
Paul Béziers, Elena Legrand, Emily Boulanger, Niladri Basu, Jessica D. Ewald, Paula Henry, Markus Hecker, Jianguo Xia, Natalie Karouna‐Renier, Doug Crump, Jessica Head   +10 more
wiley   +1 more source

A cathepsin C-like protease mediates the post-translation modification of <i>Toxoplasma gondii</i> secretory proteins for optimal invasion and egress. [PDF]

mBio, 2023
Thornton LB, Key M, Micchelli C, Stasic AJ, Kwain S, Floyd K, Moreno SNJ, Dominy BN, Whitehead DC, Dou Z.   +9 more
europepmc   +1 more source

TRANSAMIDATION REACTIONS CATALYZED BY CATHEPSIN C

Journal of Biological Chemistry, 1952
M E, JONES, W R, HEARN, M, FRIED, J S, FRUTON   +3 more
openaire   +2 more sources

Transcriptomic signatures reveal systemic adaptations and immune modulation in response to training and competitive racing in horses

Equine Veterinary Journal, EarlyView.
Abstract Background The molecular mechanisms underlying adaptation to physical exertion and racing stress in horses remain incompletely understood. Peripheral blood transcriptomics offers a minimally invasive method to monitor systemic responses to exercise and identify biomarkers of adaptation or overload. Objectives To evaluate transcriptomic changes
Izabela Dąbrowska, Jowita Grzędzicka‐Agko, Paula Kiełbik, Michał Trela, Olga Witkowska‐Piłaszewicz   +4 more
wiley   +1 more source

Coxiella burnetii manipulates the lysosomal protease cathepsin B to facilitate intracellular success

Nature Communications
The obligate intracellular bacterium Coxiella burnetii establishes an intracellular replicative niche termed the Coxiella-containing vacuole (CCV), which has been characterised as a bacterially modified phagolysosome. How C.
Lauren E. Bird, Bangyan Xu, Andrew D. Hobbs, Alexander R. Ziegler, Nichollas E. Scott, Patrice Newton, David R. Thomas, Laura E. Edgington-Mitchell, Hayley J. Newton   +8 more
doaj   +1 more source

Cysteine cathepsin C: a novel potential biomarker for the diagnosis and prognosis of glioma. [PDF]

Cancer Cell Int, 2022
Cheng X, Ren Z, Liu Z, Sun X, Qian R, Cao C, Liu B, Wang J, Wang H, Guo Y, Gao Y.   +10 more
europepmc   +1 more source

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective In the dose‐escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety/antitumor activity of FZEC in patients with platinum‐resistant ovarian cancer (PROC) from the Study 101 expansion ...
Kan Yonemori, Mayu Yunokawa, Koji Matsumoto, Kazuhiro Takehara, Kosei Hasegawa, Yasuyuki Hirashima, Hidenori Kato, Hiroki Ikezawa, Yohei Otake, Wataru Yusa, Takuma Miura, Shin Nishio   +11 more
wiley   +1 more source